| Followers | 28 |
| Posts | 22043 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Wednesday, March 04, 2026 8:16:54 AM
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
March 4, 2026 8:00 AM
PR Newswire (US)
BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html
SOURCE Edgewise Therapeutics
Original: Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Recent EWTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 12:51:21 PM
- Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline • PR Newswire (US) • 06/01/2026 12:30:00 PM
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 • PR Newswire (US) • 05/12/2026 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:20:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:09:48 PM
- Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:29:58 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:49:16 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:10:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:20 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 04/01/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:41:21 PM
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 • PR Newswire (US) • 03/04/2026 01:00:00 PM
- Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference • PR Newswire (US) • 03/03/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 03/02/2026 02:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:52 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs • PR Newswire (US) • 02/26/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 • PR Newswire (US) • 02/05/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 02/02/2026 01:00:00 PM
